BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
‘And then we saw the little head.’ Scientists witness rare sperm whale birth - 2NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby
- 3Volunteers aiding humpback whale stranded in Baltic get death threats
- 4Novartis eyes more bolt-on acquisitions, CEO says
- 5Which Breakfast Enraptures Your Taste Buds? Vote
- Israel and Iran continue tit-for-tat attacks
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Ukraine proved this drone-killer works. Now, the West is giving it a shot.
- The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Collins Foods to offload 20 Taco Bell outlets in Australia
- Wolf bites woman in a shopping area in Germany's 2nd-biggest city
- Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- Chinese mega embassy could bring security advantages, says No 10
- Building Tough Connections: Individual Bits of knowledge on Association
